'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
MELBOURNE,Australia,Sept. 11,2024-- Telix Pharmaceuticals Limited (ASX: TLX,Telix,the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lance